Overview

MARS - Monitored Atherosclerosis Regression Study

Status:
Completed

Trial end date:
1992-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Dihydromevinolin
L 647318
Lovastatin